I've been pondering the possibility of a deal for Hervaxx and how negotiations would play out.
One thing I'm wondering is if CF33 and OnCarlytics are as good as we think/hope then does that make Hervaxx redundant? I've re watched all the recent presentations and it's clear that the team at IMU are only going after gastric cancer with Hervaxx. Is it possible that a BP negotiating a deal for Hervaxx with IMU could make it conditional upon IMU not targeting gastric cancer with CF33 etc and therefore leaving that market segment available?
I have zero expertise in this field so forgive me if this is obvious or has already been addressed. Either way it would seem we have very exciting times ahead.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)